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Abstract
Background:  Numerous short-statured children are evaluated for growth hormone (GH)
deficiency (GHD). In most patients, GH provocative tests are normal and are thus in retrospect
unnecessary.
Methods: A retrospective cohort study was conducted to identify predictors of growth hormone
(GH) deficiency (GHD) in children seen for short stature, and to construct a very sensitive and
fairly specific predictive tool to avoid unnecessary GH provocative tests. GHD was defined by the
presence of 2 GH concentration peaks < 10 ng/ml. Certain GHD was defined as GHD and viewing
pituitary stalk interruption syndrome on magnetic resonance imaging. Independent predictors were
identified with uni- and multi-variate analyses and then combined in a decision rule that was
validated in another population.
Results: The initial study included 167 patients, 36 (22%) of whom had GHD, including 5 (3%) with
certain GHD. Independent predictors of GHD were: growth rate < -1 DS (adjusted odds ratio: 3.2;
95% confidence interval [1.3–7.9]), IGF-I concentration < -2 DS (2.8 [1.1–7.3]) and BMI z-score ≥
0 (2.8 [1.2–6.5]). A clinical decision rule suggesting that patients be tested only if they had a growth
rate < -1 DS and a IGF-I concentration < -2 DS achieved 100% sensitivity [48–100] for certain GHD
and 63% [47–79] for GHD, and a specificity of 68% [60–76]. Applying this rule to the validation
population (n = 40, including 13 patients with certain GHD), the sensitivity for certain GHD was
92% [76–100] and the specificity 70% [53–88].
Conclusion: We have derived and performed an internal validation of a highly sensitive decision
rule that could safely help to avoid more than 2/3 of the unnecessary GH tests. External validation
of this rule is needed before any application.
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Background
Shortness or decreasing growth is a frequent reason for
pediatric consultations. After ruling out other causes of
short stature (intestinal malabsorption, chronic liver or
kidney disease, hypothyroidism, etc), the possibility of
growth hormone (GH) deficiency (GHD) is often consid-
ered. This deficiency is associated with excess mortality
and substantial morbidity [1,2], and it can be treated.
Many children are therefore referred by their physicians to
specialist departments to test for GHD. Testing is based on
the measurement of stimulated GH secretion [3,4]: the
diagnosis is generally based on 2 GH peaks < 10 ng/mL
(or 20 mUI/mL)[4]. GHD cannot be considered certain
unless there are also one or more of the following con-
firmatory markers: familial GHD, other deficiency of the
hypothalamic-pituitary axis, micropenis, neonatal
hypoglycemia, abnormalities of the median line and pitu-
itary stalk interruption syndrome (PSIS) on magnetic res-
onance imaging (MRI) [5].
GH stimulation tests are invasive, expensive, and in view
of the risk of severe hypoglycemia [6], potentially danger-
ous [7]. Moreover they are normal in most cases and thus
retrospectively unnecessary. It would therefore be useful
to be able to identify predictive factors of GHD to avoid
these unnecessary tests. A selection strategy for GH stimu-
lation tests, however, must offer sensitivity close to 100%
for certain GHD, in view of the need to begin treatment
rapidly [8]; it must also be sufficiently specific.
Clinical (height, growth rate, difference between height
and midparental target height) [3] and laboratory (insu-
lin-like growth factor-I IGF-I]) [3,9] criteria have been
proposed to predict GHD. Used separately, these different
criteria do not fulfill the objectives described above. It
may therefore be useful to combine them. Earlier clinical
decision rules have proposed combining clinical and lab-
oratory variables [10,11] to avoid GH stimulation tests.
One rule combined growth rate and IGF-I [10], and the
other chronological age, bone age, body mass index
(BMI) and IGF-I [11]. Nonetheless the results of these
studies are limited by selection bias in patient recruitment
[10], the absence of multivariate analyses despite the very
probable correlations between variables [10], the com-
plexity of the calculations necessary to apply the rule [11],
and insufficient predictive performance [10]. This is prob-
ably why none of these tools has undergone internal or
external validation.
The objective of this study was therefore to identify the
predictive factors for GH deficiency in children consulting
for short stature and/or decreased growth rate and to con-
struct and validate internally a very sensitive and fairly
specific predictive tool that is simple to use to avoid
unnecessary tests.
Methods
Patients
This was a retrospective hospital-based cohort study. All
patients were seen by a senior pediatric endocrinologist
(RB) from January 1998 through June 2001 at Necker-
Enfants Malades Hospital in Paris, France. The Ethical
Review Committee (Comité de Protection des Personnes
Ile de France III) stated that "this research was found to
conform to generally accepted scientific principles and
research ethical standards and to be in conformity with
the laws and regulations of the country in which the
research experiment was performed" (see Additional file
1). Written informed consent of the patients or their par-
ents was not judged necessary for that kind of retrospec-
tive study.
The patients included were 1 to 16 years-old and had at
least one of the principal auxological criteria for which the
GH Research Society consensus conference guidelines
require GH stimulation testing [3] (height ≤ -3 standard
deviations (SD), growth rate ≤ -2 SD for chronological
age, or height ≤ -2 SD, growth rate ≤ -1 SD, and a differ-
ence between current height and midparental target
height > 1.5 SD). They had also had 2 tests assessing GH
secretion: one of spontaneous secretion during sleep and
one after pharmacological stimulation.
We excluded from this study the patients with conditions
other than GHD that were responsible for their short stat-
ure (hypothyroidism, celiac disease, gastrointestinal
inflammatory disease, cystic fibrosis, kidney failure, or
Turner syndrome) as well as those for which GHD was
due to a condition already known at the consultation
(lesion, surgery and/or irradiation of the hypothalamic-
pituitary region) and those with signs and findings highly
suggestive of GHD: familial GHD, history or clinical pic-
ture suggesting pituitary deficiency (polyuric-polydipsic
syndrome, severe hypoglycemia in the first months of life,
micropenis, abnormalities of the median line). Indeed,
for these high-risk patients, there is no need for a selective
strategy. Patients who had had testosterone or estradiol
priming and those with delayed puberty (defined by a
Tanner stage of 1 for a girl older than 13 years or a boy
older than 14) were also excluded.
Predicted variable
The variable to be predicted was GHD. Plasma GH (hGH
immunoradiometric assay, Immunotech, Marseille,
France) was measured for each patient from blood sam-
ples taken while sleeping (samples every 30 minutes from
22 h to 6 h) followed in the morning by a provocative test
administering arginine and insulin sequentially (arginine
0.5 g/kg intravenous perfusion for 30 min; insulin at 60
min 0.1 U/kg intravenously, n = 64), ornithine (HCl 14.5
g/m2 intravenous perfusion for 30 min, n = 73) or gluca-BMC Pediatrics 2008, 8:29 http://www.biomedcentral.com/1471-2431/8/29
Page 3 of 8
(page number not for citation purposes)
gon (0.1 mg/kg intramuscular injection, 1 mg maximum,
n = 30). During the study period, the treatment protocol
called for MRI if the 2 GH peaks were less than 10 ng/mL,
to look for PSIS (thin or interrupted stalk, ectopic poste-
rior or hypoplasic anterior pituitary gland [12]).
Children were then classified in 2 groups as a function of
the GH assay and MRI results: no GHD (1 GH peak ≥ 10
ng/mL) or GHD (2 GH peaks < 10 ng/mL). Within the
GHD group, children with pituitary stalk interruption
syndrome on MRI were considered to have certain GHD,
and the other patients were considered to have uncertain
GHD.
Potential predictors
The following potential clinical predictors were studied:
chronological age expressed in years, height measured
with a Harpenden stadiometer and expressed in SD,
growth rate expressed in SD [13], BMI measured as weight
in kilograms divided by the square of height in meters and
expressed as a z-score compared with chronological age
[14], difference in SD between height and the midparental
target height, calculated from both parents' height [15],
and pubertal stage (breast or testes) [16,17]. Two poten-
tial non clinical predictors were also studied: plasma IGF-
I (IGF-I-RIACT, Cis Bio, Gif sur Yvette, France) expressed
in SD according to chronological age [18] and bone age
delay (difference in years between chronological age and
bone age) [19].
Analysis
STATA/SE 8 (Statacorp, College Station, TX, USA) soft-
ware was used for the statistical analysis. We began by
using the Mann-Whitney test to compare the distribution
of the possibly predictive continuous variables as a func-
tion of GHD. Next, the continuous variables were dichot-
omized, either according to the standard cutoff point in
the literature or according to their distribution in patients
without GHD (median or one of the quartiles rounded to
the nearest half point). For "pubertal stage", the last 4 Tan-
ner stages were combined into one to obtain a reproduci-
ble variable (prepubertal versus pubertal children). We
conducted a bivariate analysis to study the relation
between GHD and the dichotomized variables and calcu-
late odds ratios. Comparisons were tested with the Chi-2
test or Fisher's exact test. Next, we used logistic regression
to conduct a multivariate analysis.
Decision rule derivation
First, the discriminant power of the independent variables
associated with GHD was studied by the calculation of
their sensitivity, specificity, positive predictive value and
negative predictive value for GHD and for certain GHD.
To meet our objective of high sensitivity (close to 100%)
for certain GHD with the best possible specificity (around
2/3), we varied the cutoff points of the independent pre-
dictors. Since no independent predictor used alone met
these objectives, we then combined them by recursive par-
tition to construct a decision rule, along the lines of previ-
ous rules for pediatric endocrinology [20,21]. To make the
tool simple for clinicians to use, we chose only whole val-
ues close to the standard thresholds to dichotomize the
variables.
Decision rule validation
The predictive tool was validated among 2 populations of
consecutive patients meeting the inclusion criteria
described above: a population of patients with certain
GHD seen from 1990–1998 and 2001–2005 and a popu-
lation of patients seen in 2002 with 1 GH peak ≥ 10 ng/
mL and no cause for short stature found, and thus consid-
ered not GH-deficient. The data for the validation popula-
tions remained blinded during construction of the rule,
and the rule was not modified after application to these
populations.
Results
The analysis included 167 children. Their mean age was
8.2 years (range 1.1–15.5; interquartile range 5.1–11.3)
and 49% were boys; 36 (22%) children diagnosed with
GHD, including 5 (3%) with certain GHD.
Predictive variables
Patients with GHD (Table 1) had a lower growth rate,
higher BMI, and lower IGF-I level than the patients with-
out GHD (p < 0.05). No statistically significant (p > 0.10)
difference was shown in the distribution of age, height,
difference from midparental target height, weight or bone
age delay between the two groups. After dichotomization
(Table 2), there was a statistically significant association
between GHD and growth rate < -1 SD (p = 0.005) as well
as BMI z-score ≥ 0 (p = 0.006). A trend that did not reach
statistical significance was seen between GHD and both a
prepubertal Tanner stage (p = 0.09) and IGF-I < -2 SD (p
= 0.09). No statistically significant association was
observed with age < 5 years, height < -2.5 SD, height dif-
ference with midparental target height ≥ -3 SD, weight ≥ -
2 SD (p > 0.20) or delayed bone age ≥ 1.5 years (p > 0.20).
After adjustments, GHD was not significantly (p > 0.05)
associated with a prepubertal stage (Table 2), but was sig-
nificantly and independently associated with growth rate
< -1 SD, BMI z-score ≥ 0 and IGF-I < -2 SD.
Decision rule
None of the criteria used alone allowed us to reach the
objectives we had set: sensitivity of 100% for certain GHD
and specificity ≥ 2/3 (Table 3). The best combination of
predictive independent variables was growth rate and IGF-
I (Figure 1). A clinical decision rule suggesting that GHBMC Pediatrics 2008, 8:29 http://www.biomedcentral.com/1471-2431/8/29
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stimulation testing was necessary only if these 2 indicators
(growth rate < -1 SD and IGF-I < -2 SD) were both present
yielded a specificity of 68% (95% CI [60–76]) with a sen-
sitivity of 100% (95% CI [48–100]) for the certain GHD
diagnosis. Adding BMI to this combination in a decision
tree or composite score did not improve its predictiveness.
Of the patients with uncertain GHD, 43% were not iden-
tified by the rule. These patients had a mean age of 8.5
years, a mean height of -2.3 SD, a mean growth rate of -
0.8 SD and a mean IGF-I of -2.0 SD. None had panhypo-
pituitarism and 84% had not had GH treatment.
For the periods 1990–1998 and 2001–2005, 13 patients
who met the inclusion criteria had certain GHD. The sen-
sitivity of the combination of growth rate < -1 SD and IGF-
I level < -2 SD was 92% (95% CI [76–100]). The one
patient with certain GHD who was not identified by the
rule was a 13-year-old boy with a height -2.9 SD and a
growth rate of -0.9 SD; he had no other pituitary deficien-
cies and was treated with GH. In 2002, 27 patients had at
least one GH peak ≥ 10 ng/mL and met the inclusion cri-
teria. The specificity of the predictive tool applied to this
population was 70% (95% CI [53–88]).
Discussion
Three independent predictive factors were identified
among the patients we studied: growth rate < -1 SD, IGF-I
< -2 SD and BMI z-score ≥ 0. Growth rate is a classic pre-
dictor of GHD. Different cutoff points have been pro-
posed in the literature [22-25] including the one we used
here (< -1 SD). The predictive power of the IGF-I level has
been studied repeatedly [5,9,25-29]. The results in terms
of sensitivity and specificity vary widely, but this assay is
very useful for the diagnosis of GHD [9]. The cutoff point
we used (-2 SD) is that usually found in the literature.
In our study, a BMI z-score ≥ 0 was also an independent
predictive factor of GHD. This criterion is most often con-
sidered a confounding factor instead [4]. That is, on the
one hand, children with simple obesity have an abnor-
mally low response to GH stimulation tests and on the
other hand, some children with GHD have truncal obes-
ity. Accordingly a predictive tool that uses this criterion
might therefore be dangerous. Moreover, it does not
improve the rule's predictive power.
The clinical decision rule we propose here is that GH stim-
ulation tests should be performed only on children with a
growth rate of < -1 SD and an IGF-I level < -2 SD. These
variables were also included in the rule proposed by Cian-
farani et al but with a different combination [10]. Our
decision rule has good clinical applicability because it
uses predictive variables at the rounded cutoff points
already used by clinicians. Moreover, it is probably robust
because it uses independent predictors identified by mul-
tivariate analysis. This rule should make it possible to
avoid two thirds of the GH stimulation tests that are retro-
spectively unnecessary because normal, while missing in
our series only one of 18 cases of certain GHD. This
patient had an IGF-I level < -2 SD but a growth rate of -0.9
SD. It is probable that he would have reached -1 SD dur-
ing his next follow-up, thus being "caught" by the rule.
Moreover since he did not have panhypopituitarism,
there was no immediate metabolic danger [1]. Our rule is
a relatively insensitive predictive tool for the diagnosis of
uncertain GHD: 43% of these patients were not identified.
Compensating for this poor prediction is the fact that
Table 1: Distribution of potential predictors among children with or without GHD.
Variables GHD p**
Absence of GHD Uncertain Certain
n mean SD* n mean SD* n mean SD*
History and physical examination
Age (years) 131 8.3 3.8 31 8.1 3.6 5 5.2 2.4 0.4
Height (SD) 131 -2.2 0.6 31 -2.4 0.7 5 -2.3 0.5 0.2
Weight (SD) 131 -1.7 0.8 31 -1.3 1.2 5 -1.3 1.4 0.07
Growth rate (SD) 127 -0.9 1.6 30 -1.5 1.0 5 -2.3 0.9 0.01
Difference between height and MTH*** 127 -2.1 0.9 29 -2.1 1.1 4 -3.1 0.3 0.7
BMI (z-score) 131 -0.8 1.1 31 0.0 1.4 5 0.0 2.2 0.001
Studies
IGF-I (SD) 131 -2.2 1.3 31 -2.7 1.1 5 -3.9 1.1 0.03
Bone age delay (years) 125 2.1 1.1 29 2.0 0.9 5 2.2 0.9 0.9
* Standard deviation
** Non parametric Mann-Whitney U-test (between patients with and without GHD)
*** Midparental target heightBMC Pediatrics 2008, 8:29 http://www.biomedcentral.com/1471-2431/8/29
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these patients did not have panhypopituitarism, that 84%
of them did not receive treatment, and that the abnormal
character of uncertain GHD is currently the subject of
much debate [30,31]. Indeed, GH secretion in most chil-
dren with a subnormal GH response to GH stimulation
tests but normal MRI becomes normal when they are
retested at the completion of growth or even after few
months. Thus, it is likely that many of the patients in the
uncertain GHD group did not have GHD. Some of them
have been retested (16%) and had normal GH secretion;
they may be considered to have had transient GHD. Oth-
ers reached a normal final height without treatment (7%).
The other patients are still being closely monitored for
their growth velocity.
Some of the patients (n = 5, 16%) with uncertain GHD,
and a IGF-I concentration ≥ -2 SD but a growth rate < -1
SD, would not have been identified as requiring GH secre-
tion evaluation according to the decision rule (Figure 1).
This potential false-negative rate shows the need for fol-
low-up of the growth of these patients not identified as
requiring GH secretion evaluation.
There were two potential sources of bias in our study.
First, patients came from a specialist pediatric endocrinol-
ogy outpatient department and were very probably at
higher risk of GHD than any other population. This bias
is demonstrated by the very high prevalence (22%) of
patients with GHD compared with other series [11]. We
also excluded children with priming with testosterone or
estradiol to avoid a confounding bias with IGF-I, because
we were treating it as a potential predictive variable and
priming increases both IGF-I and peak GH concentrations
[32]. Second, there may have been classification errors for
the predicted variable. That is, although stimulation tests
must be used to evaluate short children for whom GHD is
Table 2: Relations between potential predictors and GHD, before and after adjustment.
Variables Absence of GHD 
(n = 131)
GHD 
(n = 36)
OR CI p AOR* CI* pAOR*
n% n %
History and physical examination
Boys 62 47 20 56 1.4 0.7–2.9 0.4
Girls 69 53 16 44
Age < 5 years 29 22 10 28 1.4 0.6–3.1 0.5
Age ≥ 5 years 102 78 26 72
Height < -2.5 SD 48 37 16 44 1.4 0.7–2.9 0.4
Height ≥ -2.5 SD 83 63 20 56
Weight ≥ -2 SD 21 16 8 22 1.5 0.6–3.8 0.4
Weight < -2 SD 110 84 28 78
Growth rate < -1 SD 64 50 27 77 3.3 1.4–8.1 0.005 3.2 1.3–7.9 0.01
Growth rate ≥ -1 DS 63 50 8 23
Difference between height and MTH ≤ -3 SD 15 12 5 15 1.3 0.4–4.0 0.6
Difference between height and MTH > -3 SD 112 88 28 85
BMI ≥ 0 z-score 31 24 17 47 2.9 1.3–6.4 0.006 2.8 1.2–6.5 0.01
BMI < 0 z-score 100 76 19 53
Pre-pubertal children (Tanner = 1) 104 79 33 92 2.9 0.8–10 0.09 **
Pubertal children (Tanner > 1) 27 21 3 8
Studies
IGF-I < -2 SD 82 63 28 78 2.1 0.9–5.0 0.09 2.8 1.1–7.3 0.04
IGF-I ≥ -2 SD 49 37 8 22
Bone age delay ≥ 1.5 years 88 70 27 79 1.6 0.6–4.1 0.3
Bone age delay < 1.5 years 37 30 7 21
* OR adjusted for variables with a p < 0.1 in bivariate analysis (N = 162)
** Variable excluded from the model
*** Midparental target heightBMC Pediatrics 2008, 8:29 http://www.biomedcentral.com/1471-2431/8/29
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considered, their reproducibility is poor. Response varies
substantially according to the stimulus used [33]. Moreo-
ver, test response also includes a component of intraindi-
vidual variability. In a study of 40 Israeli children, Zadik
and coll. reported a moderate correlation (r = 0.52)
between 2 tests conducted 6 weeks apart with the same
pharmacological agent [34]. In our study, as in all studies
that have used stimulation tests as the reference test, clas-
sification errors may intervene between the diagnosis of
GHD (defined by 2 GH peaks < 10 ng/mL without a con-
firmation criterion) and no GHD. Errors for the certain
cases are less plausible because the criterion of certain
Patients distribution according to their growth rate (SD) and IGF-I level (SD) Figure 1
Patients distribution according to their growth rate (SD) and IGF-I level (SD).
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Table 3: Predictive values of GHD predictors.
Clinical decision rule***
Growth rate < -1 SD BMI ≥ 0 z-score IGF-I < -2 SD Construction† Validation‡
GHD All Certain All Certain All Certain All Certain
Sensitivity 77 [60–90] 100 [48–100] 47 [31–63] 60 [15–95] 78 [64–91] 100 [48–100] 63 [47–79] 100 [48–100] 92 [76–100]
Specificity 50 [41–58] Idem 76 [69–83] Idem 37 [29–46] Idem 68 [60–76] Idem 70 [53–88]
PPV* 30 [20–39] 7 [2–16] 35 [22–48] 9 [2–24] 25 [17–34] 6 [2–13] 35 [23–47] 11 [2–20] Not applicable
NPV** 89 [79–95] 100 [94–100] 84 [77–91] 98 [95–100] 86 [77–95] 100 [93–100] 87 [80–94] 100 [92–100] Not applicable
Values are expressed in % [95% CI]
* Positive predictive value
** Negative predictive value
*** To test patients with growth rate < -I SD and IGF-I < -2 SD
† Construction population
‡ Validation populationBMC Pediatrics 2008, 8:29 http://www.biomedcentral.com/1471-2431/8/29
Page 7 of 8
(page number not for citation purposes)
GHD (pituitary MRI) is more robust. Furthermore, when
we used a stimulation test cut-off of 7 ng/ml instead of 10
ng/ml to define GHD, the decision rule's sensitivity was
67% (95% CI [43–91]) (vs 63% (95% CI [47–79])) for
patients with GHD and did not change for patients with
certain GHD (100% (95% CI [48–100])). The specificity
was 64% (95% CI [56–71]) (vs 68% (95% CI [60–76])).
Conclusion
The suboptimal nature of a systematic strategy of stimula-
tion tests and the intrinsic limitations of these tests make
the construction of a predictive tool for GHD necessary.
The tool we propose is very effective for certain GHD but
far less so for uncertain GHD. The current debate about
the abnormal character of uncertain GHD [30,31] high-
lights the interest of our tool. Nonetheless, in view of the
limitations of our study and especially the low number of
patients with certain GHD, these results should be vali-
dated at other centers, as other decision rules in pediatric
endocrinology have been [21], before any widespread
clinical application.
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